TCGA-55-7227-01A-11R-2039-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.490
- INTERFERON_GAMMA_RESPONSE+0.460
- ANGIOGENESIS+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- KRAS_SIGNALING_UP+0.400
- IL6_JAK_STAT3_SIGNALING+0.390
- TGF_BETA_SIGNALING+0.390
- INFLAMMATORY_RESPONSE+0.370
- COAGULATION+0.360
Top 10 suppressed
- E2F_TARGETS-0.550
- MYC_TARGETS_V2-0.530
- G2M_CHECKPOINT-0.490
- MYC_TARGETS_V1-0.470
- OXIDATIVE_PHOSPHORYLATION-0.470
- MTORC1_SIGNALING-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.390
- DNA_REPAIR-0.380
- CHOLESTEROL_HOMEOSTASIS-0.300
- FATTY_ACID_METABOLISM-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.955 |
| 2 | TCGA-38-7271-01A-11R-2039-07 | — | cohortMD2 | 0.946 |
| 3 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.945 |
| 4 | SRR2771286 | — | — | 0.932 |
| 5 | TCGA-CV-6943-01A-11R-1915-07 | — | — | 0.930 |
| 6 | 59f108c6-677f-4cf2-89fd-6bd15133dd6f | — | — | 0.930 |
| 7 | 1b192a49-01cb-4459-a7a7-fdebe428f386 | — | — | 0.929 |
| 8 | TCGA-55-6985-01A-11R-1949-07 | — | cohortA1 | 0.927 |
| 9 | SRR12202441 | — | — | 0.927 |
| 10 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.923 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.410 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |